Matsui venture capital bill (HR 420) endorsed by BIO in House testimony.
Executive Summary
HR 420 VENTURE CAPITAL INCENTIVES SUPPORTED BY BIO in testimony delivered by Connective Therapeutics CEO Tom Wiggans during a March 19 hearing of the House Ways & Means Committee on the Clinton Administration's FY 1998 budget request. Wiggans endorsed House legislation (HR 420) introduced by Reps. Matsui (D-Calif.), English (R-Penn.) and McCrery (R-La.). The Matsui bill is a reprise of legislation introduced during the 104th Congress ("The Pink Sheet" June 26, 1995, T&G-3).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth